Saint-Gobain Presents Expanded Portfolio of Made-to-Order Single-Use Solutions at Interphex


Tailored systems help bio-processors enhance product integrity and process efficiency



Taunton, MA – The Biopharmaceutical group of Saint-Gobain Performance Plastics (SGPPL) is showcasing its expanded line of single-use technologies for biopharmaceutical manufacturing applications at booth #1636 in the Manufacturing & Packaging Zone of Interphex 2013 (April 23-25; Jacob K. Javits Center, New York City, NY). With the recent acquisitions of American Fluoroseal Corporation, Twin Bay Medical and Applied Bioprocess Containers, SGPPL has significantly expanded its portfolio of best-in-class single-use technologies – and expertise – to offer a complete systems approach in building tailored single-use or hybrid systems that meet the needs of even the most demanding biopharmaceutical applications.



For bioprocessors, maintaining product integrity throughout the production cycle is critical to ensuring a safe, high-quality and profitable product. As fluids reach downstream operations where product nears completion, they become more valuable and require even greater protection against possible sterility breaches that can turn whole batches into costly waste. Single-use systems help biopharmaceutical manufactures ensure the integrity of their products by preventing contamination between lots. Because these systems adhere to rigorous regulations on sterilization procedures, companies can comply with mandates without sacrificing efficiency. 



The recent acquisitions have added several technologies to SGPPL's existing range of single-use offerings – such as the BarbLock® line of ultra-secure retainers with full 360° radial crimp and compression for connective applications in biopharmaceutical transport systems, flexible tubing and hose, disposable assemblies and medical equipment.



Additionally, SGPPL offers Sani-Tech® and C-Flex® families of solutions that include molded manifolds for a wide range of applications in pharmaceutical and biotech development and processing. Products like BarbLock retainers and Sani-Tech and C-Flex molded manifolds can be combined within an end-user’s systems to offer advanced product protection downstream.



Beyond protecting product integrity, single-use systems can also help bioprocessors maintain and enhance process efficiency. These products and systems reduce the risk of batch-to-batch contamination without the costly and time-consuming cleaning validation required for conventional/reusable hard-plumbed equipment. Additionally, by collaborating with customers to evaluate fluid handling strategies at each process step, SGPPL can provide recommendations on tools to increase efficiency in the handling of fluids throughout the production process. For example, the company's expanded range of single-use components and devices offer powerful degrees of modularity. This enables operators to swap technologies in and out between batches of different products, maximizing the versatility of facilities.



The result is a robust variety of solutions that can be leveraged in designing and customizing complete single-use or hybrid systems for numerous uses. These applications may involve cell cultures, vessel and tank transfer, pumps, cold storage, fluid/drug delivery and sterile filling and dispensing.



"Biopharmaceutical manufacturers are faced with rigorous regulatory and competitive pressures that continue to drive the adoption of single-use technologies," said Anthony Pagliaro Jr., Worldwide Marketing Director, Saint-Gobain Performance Plastics. "Saint-Gobain is uniquely positioned to design custom single-use and hybrid systems for a broad range of biopharmaceutical applications, providing unprecedented process flexibility, enhancing product safety and slimplifying regulatory compliance while reducing costs for our customers over time."



To learn more about the design and customization capabilities offered by SGPPL for single-use systems, visit http://www.biopharm.saint-gobain.com/en/index.asp.



About The Biopharmaceutical group of Saint-Gobain Performance Plastics



The Biopharmaceutical group of Saint-Gobain Performance Plastics combines technical expertise, global manufacturing capabilities, market knowledge and the sophisticated research and development resources of Saint-Gobain to meet the evolving needs of pharmaceutical, biotech, consumer and animal health, and OEM customers around the world. To learn more, visit http://www.biopharm.saint-gobain.com/en/index.asp.



About Saint-Gobain Performance Plastics (SGPPL)



Saint-Gobain Performance Plastics and its family of companies have supplied high-performance polymers for the most demanding applications for more than five decades. Our tradition of excellence can be traced back more than 300 years through our parent company, Saint-Gobain, one of the world's top 100 industrial corporations, with operations in nearly 64 countries and more than 190,000 employees. Saint-Gobain's commitment to quality is reflected in our leadership position in the four major market segments we serve: construction products, innovative materials, building distribution and packaging.



Christina Grasso

ABI, Inc.

29 Broadway

Suite 1300

New York, NY 10006

+1 (212) 529-2541 

cgrasso@abipr.com


More from Laboratory and Research Supplies and Equipment

All Topics